Fotivda (Tivozanib) 0.89mg — Targeted Therapy for Advanced Kidney Cancer

Fotivda (Tivozanib) 0.89mg is an oral, highly selective VEGFR tyrosine‑kinase inhibitor developed for adults with advanced renal cell carcinoma. By blocking vascular endothelial growth factor receptors, it restricts tumor angiogenesis, helping slow tumor growth and disease progression. Designed for patients whose cancer has returned or not responded to previous systemic therapies, Tivozanib provides targeted efficacy with a once‑daily dosing strategy to support long‑term management.